Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
Date
2019Author
Sezer, A.
Tural, D.
Korkmaz, T.
Paydas, S.
Yilmaz, C.
Turna, H.
Beypinar, I.
Cinkir, H. Yesil
Okutur, K.
Erman, M.
Cabuk, D.
Isikdogan, A.
Demirkazik, A.
Karaoglu, A.
Yazilitas, D.
ŞENLER, FİLİZ ÇAY
Yumuk, P. F.
Coskun, H.
Yildiz, I.
Oztop, I.
Aydin, K.
Kaplan, M.
Meydan, N.
Olmez, O. F.
Ozyilkan, O.
Seber, S.
Arslan, C.
Sendur, M. A.
Cicin, I.
Eralp, Y.
Kilickap, S.
Demirci, U.
Bugdayci, F.
Metadata
Show full item recordCollections
- Makale [92796]